ZID BC 011517 (ZID) | |||
---|---|---|---|
Title | Pediatric Oncology Branch Behavioral Science Core | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Glod, John | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $865,625 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Behavioral and Social Science (100.0%) Cancer (100.0%) Cancer Survivorship (75.0%) Neurofibromatosis (50.0%) Childhood Cancers (100.0%) |
Brain (50.0%) Nervous System (100.0%) |
||
Research Type | |||
Patient Care and Survivorship Issues End-of-Life Care |
|||
Abstract | |||
The Core staff scientists conduct behavioral research as part of collaborative medical protocols to support multiple principal investigators in the NCI and lead their own research studies by assessing psychosocial, quality of life, and/or neurocognitive outcomes in the following studies: Phase II trial of DNA methyl transferase inhibitor, SGI-110, in children and adults wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer (PI: John Glod); longitudinal study of children undergoing radiation for brain tumors (PI: Kathy Warren); Assessing neurotoxicity using computerized neurocognitive testing and a neurologic symptom checklist that we developed in a POB phase I CD22 CAR treatment protocol for children with recurrent B-cell malignancies (PI: Nirali Shah); Assessing neurotoxicity using computerized neurocognitive testing and a neurologic symptom checklist that we developed and revised based on the CD22 CAR results in the new POB phase I CD19/22 CAR treatment protocol for children with recurrent B-cell malignancies (PI: Nirali Shah); and a new Phase I Dose Escalation Study of Anti-FGFR4 Chimeric Antigen Receptor T Cells in Children and Young Adults with Recurrent or Refractory Rhabdomyosarcoma (PI: Javed Kahn); Planning the cognitive assessment for a new protocol that is evaluating the effects of Bryostatin-1. This agent is being evaluated to determine its ability to increase surface expression of CD22 in patients with ALL to potentially improve response to anti-CD22 targeted therapies but also to assess its ability to improve cognitive late effects as this drug improves cognitive function in patients with Alzheimer's disease (PI: Nirali Shah); a trial of convection-enhanced delivery of IL-13 in children with progressive pediatric diffuse infiltrating brainstem gliomas and supratentorial high-grade gliomas(PI: Kathy Warren); a longitudinal and natural history study of children and young adults with Medullary Thyroid Carcinoma (MTC) (PI: Brigitte Widemann); Phase II trial of Vandetanib in children and adults with Gastrointestinal Stromal Tumor (GIST) (PI: Brigitte Widemann); Phase II trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) inhibitor Selumetinib (AZD6244 hydrogen sulfate) in Patients with Neurofibromatosis Type 1 (NF1) related Gastrointestinal Stomal Tumors (GIST) (PI: Brigitte Widemann); Identifying patient and parent attitudes toward the use of next generation sequencing (NGS) for diagnosing and managing cancer and the return of results and incidental findings (PI: Rosie Kaplan); Investigating the natural history of neuropsychological functioning, QOL, and pain in children, adolescents, and young adults with NF1 (PI: Brigitte Widemann); phase II clinical trial of selumetinib in children with NF1 and inoperable plexiform neurofibromas, contributing to the statistical analysis plan, and preparing the PRO data for FDA review.a phase II clinical trial of selumetinib in adults with NF1 and inoperable plexiform neurofibromas. Assessing medication adherence in a phase II clinical trial of selumetinib in children with NF1 and inoperable plexiform neurofibromas. Designing and leading the QOL and pain studies as part of several international consortium clinical trials and POB treatment protocols for children and adults with NF1. Investigating neurocognitive functions, pain, and quality of life in three protocols of children, adolescents, and adults with sickle cell anemia undergoing stem cell transplant (PIs: Courtney Fitzhugh, John Tisdale); Evaluating the effects of whole-brain radiation on the neurocognitive functioning of adults with brain tumor metastases (PI: Kevin Camphausen); Assessing the feasibility and utility of PROMIS measures in pediatric cancer caregivers (PI: Margaret Bevans); Assessing psychosocial characteristics of children in a natural history study of clinical factors in children with chronic GVHD (PI: Steven Pavleti |